vessel and to stent type (bare metal stent (BMS) or drug-eluting stent (DES)). The results were adjusted for background, and procedural factors. The primary outcome variables were mortality, restenosis and stent thrombosis (ST). Results: 7840 patients treated for a single proximal stenosis were identified. DES was used in 35.5% of patients. The use of DES as compared to BMS in the proximal LAD was associated with a lower restenosis rate (HR 0.39 CI 0.27-0.55), a lower mortality (HR 0.58 CI 0.41-0.82) and a non-significant reduction in ST (HR 0.48 CI 0.12-1.91) However, in the proximal RCA and LCX, DES was not associated with a lower restenosis rate respectively), or mortality (HR 1.48 CI 0.92-2.40, HR 0.80 CI 0.39-1.63, respectively). There was no difference in ST rate in the RCA (HR 1.24 CI 0.65-2.39). In the LCX there were too few ST events to allow meaningful evaluation.
Background: The SYNTAX Score (SS) is a useful angiographic tool to manage patients with multivessel coronary artery disease (CAD) requiring coronary revascularization. Discrepancy in SS between cath-lab personnel has been published. However, the score variability and impact in every type of lesion has not reported. Our purpose was to assess interobserver variability and impact in SS within lesion characteristics. Methods: We selected coronary angiograms with left main and/or three-vessel CAD disease without previous revascularization. After completing the basic training available at the official SS website, two interventional cardiologists (IC) calculated global (nϭ98 patients, 413 lesions) as well as per lesion SS (in 209/413 lesions, 50.6%). We analysed global variability (Kappa and Bland Altman), per-lesion inter-observer variability (percentage of agreement and Kappa) and impact (percentage of total error observed and multivariable model if discrepancy between observers was Ͼ 3 points per lesion). Results: Global SS interobserver variability was acceptable: Kappa 0,70 (0,59 -0,81). Visual analysis through Bland Altman was good, without systematic errors. Mild disagreement in the total lesions per patient were observed between both IC (difference 0.33 lesions, K value 0,76).Per-lesion discrepancy and impact concerning adverse characteristic scoring is detailed in TableI. Disagreements Ͼ 3 points per lesion analyzed was observed in 21,1%. This discrepancy corresponded 61% of the global SS error. Background: Everolimus-eluting stents (EES) reduce target lesion revascularization (TLR) compared to bare metal stents (BMS), but cost more. Whether the increased costs of EES are offset by reductions in costs of adverse clinical outcomes compared to BMS is uncertain. Methods: Percutaneous coronary intervention with EES (nϭ1,024) and BMS (nϭ819) were performed at a single center (Wake Forest Baptist Medical Center) between January 2007 and December 2010. One year clinical outcomes and costs in 2010 dollars were prospectively evaluated and compared for propensity score matched patients. Follow-up was Ͼ94% for both groups. Results: Baseline characteristics were similar for matched EES and BMS (nϭ714 for both). Clopidogrel use at 1 year was 87% EES vs. 61% BMS (pϽ0.001). Initial cost difference between DES and BMS was almost entirely offset by lower repeat revascularization costs at 1 year (⌬5.6/100 patients), with clopidogrel costs representing 97% of the remaining cost difference. Aggregate 1-year costs were $456 more ($508 less to $1,291 more) with EES (pϭ0.32), yielding an incremental cost effectiveness ratio of $8,135 per TLR avoided with EES. The cost effectiveness profile of EES was highly sensitive to cost of clopidogrel. 
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